secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2022-05-16T23:59:59+00:00
Accession:  0001193125-22-150889
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos Therapeutics reports Q1 net loss of $9.8M; first patient dosed in TCR-T Library trial
--------------------------------------------------------------------------------

- Net loss $9.8M ($0.05/sh) vs $21.6M ($0.10) in Q1 2021; cash $68.3M.
- First patient dosed in TCR-T Library Phase 1/2 trial targeting KRAS, TP53, EGFR mutations across six solid tumors.
- R&D expenses $5.6M (-58%), G&A $3.5M (-57%), operating cash burn $7.8M (-49%).
- Preclinical data on mbIL-15 presented at ASGCT; IND expected H2 2023.
- Initial clinical data expected H2 2022; cash runway into Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/0001193125-22-150889-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312522150889/d359627d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-150889

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer